{"type": "root", "children": [{"type": "p", "children": [{"type": "t", "text": "\nLong non‐coding RNAs (lncRNAs) are increasingly recognized as key regulators in both oncogenesis and metabolic disorders. Among them, VIM‑AS1 has emerged as a multifunctional molecule whose dysregulation is linked to diverse pathologies. In colorectal cancer, for instance, VIM‑AS1 is markedly upregulated in high‑grade tumors with lymph node metastasis and vascular invasion, where it promotes tumor proliferation, apoptosis resistance, and epithelial‑to‑mesenchymal transition (EMT) to drive invasion and migration."}, {"type": "fg", "children": [{"type": "fg_f", "ref": "1"}]}, {"type": "t", "text": " Moreover, differential levels of VIM‑AS1 have been associated with type 2 diabetes (T2D) susceptibility, suggesting that its regulatory functions extend into metabolic control."}, {"type": "fg", "children": [{"type": "fg_f", "ref": "2"}]}, {"type": "t", "text": "\n"}]}, {"type": "t", "text": "\n\n"}, {"type": "p", "children": [{"type": "t", "text": "\nAdditional studies have highlighted the involvement of VIM‑AS1 in cancers beyond the colon. In prostate cancer, altered expression of VIM‑AS1 is linked to disease progression, supporting its role as a modulator of tumor cell behavior."}, {"type": "fg", "children": [{"type": "fg_f", "ref": "3"}]}, {"type": "t", "text": " Its impact is not limited to malignant tumors; emerging research also implicates VIM‑AS1 in the pathogenesis of diabetic complications such as diabetic retinopathy."}, {"type": "fg", "children": [{"type": "fg_f", "ref": "4"}]}, {"type": "t", "text": " Furthermore, in glioma, VIM‑AS1 contributes to tumorigenesis by regulating the miR‑105‑5p/WEE1 signaling axis, thereby influencing cell cycle control."}, {"type": "fg", "children": [{"type": "fg_f", "ref": "5"}]}, {"type": "t", "text": "\n"}]}, {"type": "t", "text": "\n\n"}, {"type": "p", "children": [{"type": "t", "text": "\nMechanistic investigations in other cancer types further expand the functional repertoire of VIM‑AS1. In gastric cancer, for example, VIM‑AS1 enhances cell proliferation, migration, invasion, and EMT through upregulation of frizzled 1 and subsequent activation of the Wnt/β‑catenin pathway—a finding that correlates with poorer patient prognosis."}, {"type": "fg", "children": [{"type": "fg_f", "ref": "6"}]}, {"type": "t", "text": " Similarly, in oral squamous cell carcinoma, elevated VIM‑AS1 is associated with increased vimentin and decreased E‑cadherin expression, reinforcing its role in EMT and tumor aggressiveness."}, {"type": "fg", "children": [{"type": "fg_f", "ref": "7"}]}, {"type": "t", "text": " Finally, in castration‑resistant prostate cancer, VIM‑AS1 not only drives proliferation but also confers resistance to anti‑androgen therapy by stabilizing HMGCS1 mRNA through formation of an IGF2BP2‑containing ribonucleoprotein complex, thus positioning it as a promising therapeutic target."}, {"type": "fg", "children": [{"type": "fg_f", "ref": "8"}]}, {"type": "t", "text": "\n"}]}, {"type": "rg", "children": [{"type": "r", "ref": 1, "children": [{"type": "t", "text": "Hajar Rezanejad Bardaji, Malek Hossein Asadi, Mohammad Mehdi Yaghoobi "}, {"type": "b", "children": [{"type": "t", "text": "Long noncoding RNA VIM-AS1 promotes colorectal cancer progression and metastasis by inducing EMT."}]}, {"type": "t", "text": " "}, {"type": "i", "children": [{"type": "t", "text": "Eur J Cell Biol (2018)"}]}, {"type": "t", "text": " DOI: "}, {"type": "a", "children": [{"type": "t", "text": "10.1016/j.ejcb.2018.04.004"}], "href": "https://doi.org/10.1016/j.ejcb.2018.04.004"}, {"type": "t", "text": " PMID: "}, {"type": "a", "children": [{"type": "t", "text": "29656793"}], "href": "https://pubmed.ncbi.nlm.nih.gov/29656793"}]}, {"type": "r", "ref": 2, "children": [{"type": "t", "text": "Maryam Erfanian Omidvar, Hamid Ghaedi, Faranak Kazerouni, et al. "}, {"type": "b", "children": [{"type": "t", "text": "Clinical significance of long noncoding RNA VIM-AS1 and CTBP1-AS2 expression in type 2 diabetes."}]}, {"type": "t", "text": " "}, {"type": "i", "children": [{"type": "t", "text": "J Cell Biochem (2019)"}]}, {"type": "t", "text": " DOI: "}, {"type": "a", "children": [{"type": "t", "text": "10.1002/jcb.28206"}], "href": "https://doi.org/10.1002/jcb.28206"}, {"type": "t", "text": " PMID: "}, {"type": "a", "children": [{"type": "t", "text": "30506719"}], "href": "https://pubmed.ncbi.nlm.nih.gov/30506719"}]}, {"type": "r", "ref": 3, "children": [{"type": "t", "text": "Yifeng Zhang, Jiong Zhang, Suyu Liang, et al. "}, {"type": "b", "children": [{"type": "t", "text": "Long non-coding RNA VIM-AS1 promotes prostate cancer growth and invasion by regulating epithelial-mesenchymal transition."}]}, {"type": "t", "text": " "}, {"type": "i", "children": [{"type": "t", "text": "J BUON (2019)"}]}, {"type": "t", "text": " PMID: "}, {"type": "a", "children": [{"type": "t", "text": "31786880"}], "href": "https://pubmed.ncbi.nlm.nih.gov/31786880"}]}, {"type": "r", "ref": 4, "children": [{"type": "t", "text": "Feng Zeng, Gang Luo, Yamei Lu, et al. "}, {"type": "b", "children": [{"type": "t", "text": "Long non-coding RNA VIM Antisense RNA 1 (VIM-AS1) sponges microRNA-29 to participate in diabetic retinopathy."}]}, {"type": "t", "text": " "}, {"type": "i", "children": [{"type": "t", "text": "Acta Diabetol (2020)"}]}, {"type": "t", "text": " DOI: "}, {"type": "a", "children": [{"type": "t", "text": "10.1007/s00592-020-01536-2"}], "href": "https://doi.org/10.1007/s00592-020-01536-2"}, {"type": "t", "text": " PMID: "}, {"type": "a", "children": [{"type": "t", "text": "32447557"}], "href": "https://pubmed.ncbi.nlm.nih.gov/32447557"}]}, {"type": "r", "ref": 5, "children": [{"type": "t", "text": "S-T Suo, P Gong, X-J Peng, et al. "}, {"type": "b", "children": [{"type": "t", "text": "Knockdown of long non-coding RNA VIM-AS1 inhibits glioma cell proliferation and migration, and increases the cell apoptosis via modulation of WEE1 targeted by miR-105-5p."}]}, {"type": "t", "text": " "}, {"type": "i", "children": [{"type": "t", "text": "Eur Rev Med Pharmacol Sci (2020)"}]}, {"type": "t", "text": " DOI: "}, {"type": "a", "children": [{"type": "t", "text": "10.26355/eurrev_202006_21673"}], "href": "https://doi.org/10.26355/eurrev_202006_21673"}, {"type": "t", "text": " PMID: "}, {"type": "a", "children": [{"type": "t", "text": "32633376"}], "href": "https://pubmed.ncbi.nlm.nih.gov/32633376"}]}, {"type": "r", "ref": 6, "children": [{"type": "t", "text": "Jin-Gui Sun, Xiao-Bo Li, Rui-Hong Yin, et al. "}, {"type": "b", "children": [{"type": "t", "text": "lncRNA VIM‑AS1 promotes cell proliferation, metastasis and epithelial‑mesenchymal transition by activating the Wnt/β‑catenin pathway in gastric cancer."}]}, {"type": "t", "text": " "}, {"type": "i", "children": [{"type": "t", "text": "Mol Med Rep (2020)"}]}, {"type": "t", "text": " DOI: "}, {"type": "a", "children": [{"type": "t", "text": "10.3892/mmr.2020.11577"}], "href": "https://doi.org/10.3892/mmr.2020.11577"}, {"type": "t", "text": " PMID: "}, {"type": "a", "children": [{"type": "t", "text": "33173977"}], "href": "https://pubmed.ncbi.nlm.nih.gov/33173977"}]}, {"type": "r", "ref": 7, "children": [{"type": "t", "text": "Esra Bozgeyik, Bilal Ege, Mehtap Koparal, et al. "}, {"type": "b", "children": [{"type": "t", "text": "Clinical significance of Vimentin Antisense RNA 1 and its correlation with other epithelial to mesenchymal transition markers in oral cancers."}]}, {"type": "t", "text": " "}, {"type": "i", "children": [{"type": "t", "text": "Pathol Res Pract (2022)"}]}, {"type": "t", "text": " DOI: "}, {"type": "a", "children": [{"type": "t", "text": "10.1016/j.prp.2022.153807"}], "href": "https://doi.org/10.1016/j.prp.2022.153807"}, {"type": "t", "text": " PMID: "}, {"type": "a", "children": [{"type": "t", "text": "35202907"}], "href": "https://pubmed.ncbi.nlm.nih.gov/35202907"}]}, {"type": "r", "ref": 8, "children": [{"type": "t", "text": "Sheng-Jia Shi, Dong-Hui Han, Jing-Liang Zhang, et al. "}, {"type": "b", "children": [{"type": "t", "text": "VIM‑AS1 promotes proliferation and drives enzalutamide resistance in prostate cancer via IGF2BP2‑mediated HMGCS1 mRNA stabilization."}]}, {"type": "t", "text": " "}, {"type": "i", "children": [{"type": "t", "text": "Int J Oncol (2023)"}]}, {"type": "t", "text": " DOI: "}, {"type": "a", "children": [{"type": "t", "text": "10.3892/ijo.2023.5482"}], "href": "https://doi.org/10.3892/ijo.2023.5482"}, {"type": "t", "text": " PMID: "}, {"type": "a", "children": [{"type": "t", "text": "36734275"}], "href": "https://pubmed.ncbi.nlm.nih.gov/36734275"}]}]}]}